Molecularly targeted therapies in breast cancer bone metastases.
Clézardin
Philippe
P
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001853:Bone Marrow; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018925:Chemokines / Q000378:metabolism; D004164:Diphosphonates / Q000627:therapeutic use; D005260:Female; D006801:Humans; D010006:Osteoblasts / Q000378:metabolism; D010010:Osteoclasts / Q000378:metabolism; D053245:RANK Ligand / Q000037:antagonists & inhibitors / Q000378:metabolism; D053246:Receptor Activator of Nuclear Factor-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism; D019707:Receptors, Chemokine / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D016212:Transforming Growth Factor beta / Q000378:metabolism
D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D018925:Chemokines; D004164:Diphosphonates; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D019707:Receptors, Chemokine; D016212:Transforming Growth Factor beta